• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishDashboard
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI employees
    Legal
    Terms of usePrivacy policyCookie policy

    SEC Form POS AM filed by DICE Therapeutics Inc.

    8/9/23 9:32:26 AM ET
    $DICE
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Get the next $DICE alert in real time by email
    POS AM 1 d513885dposam.htm POS AM POS AM

    As filed with the Securities and Exchange Commission on August 9, 2023

    Registration No. 333-267702

     

     

     

    UNITED STATES

    SECURITIES AND EXCHANGE COMMISSION

    Washington, D.C. 20549

     

     

    POST-EFFECTIVE AMENDMENT NO. 1

    TO

    FORM S-3

    REGISTRATION STATEMENT

    UNDER

    THE SECURITIES ACT OF 1933

     

     

    DICE THERAPEUTICS, INC.

    (Exact name of registrant as specified in its charter)

     

     

     

    Delaware   47-2286244

    (State or other jurisdiction of

    incorporation or organization)

     

    (I.R.S. Employer

    Identification Number)

    400 East Jamie Court, Suite 300

    South San Francisco, California 94080

    (650) 566-1420

    (Address, including zip code, and telephone number, including area code, of registrant’s principal executive offices)

    Philip L. Johnson

    President

    DICE Therapeutics, Inc.

    Lilly Corporate Center

    Indianapolis, Indiana 46285

    (Name and address of agent for service)

    (317) 276-2000

    (Name, address, including zip code, and telephone number, including area code, of agent for service)

    Copy to:

    Sophia Hudson, P.C.

    Julia Danforth

    Kirkland & Ellis LLP

    601 Lexington Avenue

    New York, New York 10022

    Telephone: (212) 446-4800

    (Approximate date of commencement of proposed sale to the public): Not applicable.

     

     

    If the only securities being registered on this Form are being offered pursuant to dividend or interest reinvestment plans, please check the following box:  ☐

    If any of the securities being registered on this Form are to be offered on a delayed or continuous basis pursuant to Rule 415 under the Securities Act of 1933, other than securities offered only in connection with dividend or interest reinvestment plans, check the following box:  ☐

    If this Form is filed to register additional securities for an offering pursuant to Rule 462(b) under the Securities Act, please check the following box and list the Securities Act registration statement number of the earlier effective registration statement for the same offering.  ☐

    If this Form is a post-effective amendment filed pursuant to Rule 462(c) under the Securities Act, check the following box and list the Securities Act registration statement number of the earlier effective registration statement for the same offering.  ☐

    If this Form is a registration statement pursuant to General Instruction I.D. or a post-effective amendment thereto that shall become effective upon filing with the Commission pursuant to Rule 462(e) under the Securities Act, check the following box.  ☐

    If this Form is a post-effective amendment to a registration statement filed pursuant to General Instruction I.D. filed to register additional securities or additional classes of securities pursuant to Rule 413(b) under the Securities Act, check the following box.  ☐

    Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, a smaller reporting company, or an emerging growth company. See the definitions of “large accelerated filer,” “accelerated filer,” “smaller reporting company,” and “emerging growth company” in Rule 12b-2 of the Exchange Act.

     

    Large accelerated filer   ☐    Accelerated filer   ☐
    Non-accelerated filer   ☒    Smaller reporting company   ☒
         Emerging growth company   ☒

    If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 7(a)(2)(B) of the Securities Act.  ☐

     

     

     


    DEREGISTRATION OF SECURITIES

    This Post-Effective Amendment No. 1 (this “Post-Effective Amendment”) relates to the Registration Statement on Form S-3 (File No. 333-267702) (the “Registration Statement”) filed by DICE Therapeutics, Inc. (the “Registrant”) with the U.S. Securities and Exchange Commission (the “Commission”) on October 3, 2022 and declared effective by the Commission on October 7, 2022, registering the issuance and sale by the Registrant of up to $400,000,000 of the Registrant’s common stock, par value $0.0001 per share, preferred stock, par value $0.0001 per share, debt securities, warrants to purchase the Registrant’s common stock, preferred stock or debt securities, subscription rights to purchase the Registrant’s common stock, preferred stock or debt securities and/or units consisting of some or all of these securities.

    On August 9, 2023, pursuant to the Agreement and Plan of Merger, dated as of June 18, 2023 (the “Merger Agreement”), by and among the Registrant, Eli Lilly and Company (“Parent”) and Durning Acquisition Corporation (“Purchaser”), Purchaser merged with and into the Registrant (the “Merger”), with the Registrant surviving such Merger as a wholly-owned subsidiary of Parent. As a result of the transactions contemplated by the Merger Agreement, the Registrant has terminated any and all offerings and sales of securities pursuant to the Registration Statement. In accordance with an undertaking made by the Registrant in the Registration Statement to remove from registration, by means of a post-effective amendment, any of the securities of the Registrant registered under the Registration Statement which remain unsold at the termination of the offering, the Registrant hereby terminates the effectiveness of the Registration Statement and removes from registration all of the securities that remain unsold under the Registration Statement as of the date hereof, if any.

    The Registrant is filing this Post-Effective Amendment to withdraw and remove from registration all securities registered pursuant to the Registration Statement that remain unsold as of the date hereof. The Registration Statement is hereby amended, as appropriate, to reflect the deregistration of such securities. After giving effect to this Post-Effective Amendment, there will be no remaining securities registered by the Registrant pursuant to the Registration Statement.


    SIGNATURE

    Pursuant to the requirements of the Securities Act of 1933, as amended, the registrant certifies that it has reasonable grounds to believe that it meets all of the requirements for filing on Form S-3 and has duly caused this Post-Effective Amendment to be signed on its behalf by the undersigned, thereunto duly authorized, in the City of Indianapolis, Indiana, on August 9, 2023.

     

    DICE THERAPEUTICS, INC.
    By:  

    /s/ Philip L. Johnson

    Name:   Philip L. Johnson
    Title:   President

    Pursuant to Rule 478 under the Securities Act of 1933, as amended, no other person is required to sign this Post-Effective Amendment.

    Get the next $DICE alert in real time by email

    Chat with this insight

    Save time and jump to the most important pieces.

    Recent Analyst Ratings for
    $DICE

    DatePrice TargetRatingAnalyst
    5/24/2023$38.00Equal Weight
    Wells Fargo
    5/22/2023$71.00Buy
    Canaccord Genuity
    3/31/2023$56.00Buy
    Needham
    3/1/2023Outperform
    TD Cowen
    3/1/2023Outperform
    Cowen
    11/15/2022$65.00Buy
    Guggenheim
    9/14/2022$36.00Overweight
    Cantor Fitzgerald
    9/7/2022$37.00Buy
    Stifel
    More analyst ratings

    $DICE
    Financials

    Live finance-specific insights

    See more
    • Lilly Completes Acquisition of DICE Therapeutics

      INDIANAPOLIS, Aug. 9, 2023 /PRNewswire/ -- Eli Lilly and Company (NYSE: LLY) today announced the successful completion of its acquisition of DICE Therapeutics, Inc. (NASDAQ:DICE). The acquisition expands Lilly's immunology portfolio to include DICE's novel oral therapeutic candidates, including oral IL-17 inhibitors currently in clinical development, to treat chronic diseases in immunology. "Since our founding nearly 150 years ago, we've strived to make life better for people around the world – but we know that to achieve this goal, we have to bring the brightest minds to Lilly," said Ajay Nirula, Ph.D., senior vice president of immunology at Lilly. "With the passion and expertise of our new

      8/9/23 9:02:00 AM ET
      $DICE
      $LLY
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • DICE Therapeutics Announces Positive Topline Data from Phase 1 Clinical Trial of Lead Oral IL-17 Antagonist, DC-806, for Psoriasis

      Clinical proof-of-concept in psoriasis patients achieved with a mean percentage reduction in PASI from baseline at 4 weeks of 43.7% in the high dose group compared to 13.3% in the placebo group, with an exploratory p-value of 0.0008 DC-806 was well tolerated with an excellent safety profile across all dose groups in healthy volunteers and psoriasis patients with a robust PK profile and clear pharmacodynamic effects on two distinct biomarkers at both high and low doses of DC-806 Data supports further development of DC-806 as potential best-in-class oral agent for psoriasis; DC-806 is expected to advance into a Phase 2b clinical trial in the first half of 2023 Company to host conference cal

      10/11/22 7:00:00 AM ET
      $DICE
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $DICE
    Press Releases

    Fastest customizable press release news feed in the world

    See more
    • Lilly Completes Acquisition of DICE Therapeutics

      INDIANAPOLIS, Aug. 9, 2023 /PRNewswire/ -- Eli Lilly and Company (NYSE: LLY) today announced the successful completion of its acquisition of DICE Therapeutics, Inc. (NASDAQ:DICE). The acquisition expands Lilly's immunology portfolio to include DICE's novel oral therapeutic candidates, including oral IL-17 inhibitors currently in clinical development, to treat chronic diseases in immunology. "Since our founding nearly 150 years ago, we've strived to make life better for people around the world – but we know that to achieve this goal, we have to bring the brightest minds to Lilly," said Ajay Nirula, Ph.D., senior vice president of immunology at Lilly. "With the passion and expertise of our new

      8/9/23 9:02:00 AM ET
      $DICE
      $LLY
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Lilly Announces Extension of Tender Offer to Acquire DICE

      INDIANAPOLIS, July 25, 2023 /PRNewswire/ -- Eli Lilly and Company (NYSE:LLY) today announced the extension of the expiration of the tender offer to acquire all of the issued and outstanding shares ("Shares") of common stock of DICE Therapeutics, Inc. (NASDAQ:DICE), for a purchase price of $48 per share in cash, without interest and less any applicable tax withholding. The tender offer, which was previously scheduled to expire one minute past 11:59 p.m., Eastern time, on July 28, 2023, has been extended until one minute past 11:59 p.m., Eastern time, on Aug. 8, 2023, unless the tender offer is further extended or earlier terminated. The proposed acquisition is expected to close in the third q

      7/25/23 6:55:00 AM ET
      $DICE
      $LLY
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Lifshitz Law PLLC Announces Investigations of BG, KDNY, QUOT, and DICE

      NEW YORK, June 24, 2023 (GLOBE NEWSWIRE) -- Bunge Limited (NYSE:BG) Lifshitz Law PLLC announces an investigation into possible breach of fiduciary duties in connection with the merger of BG and Viterra Limited. Under the terms of the agreement, Viterra Limited shareholders will receive approximately 65.6 million shares of BG common stock and $2.0 billion in cash. In addition, BG will assume $9.8 billion of Viterra Limited debt and BG plans to repurchase $2.0 billion of BG common stock. If you are a BG investor, and would like additional information about our investigation, please complete the Information Request Form or contact Joshua Lifshitz, Esq. by telephone at (516)493-9780 or e-m

      6/24/23 8:11:00 PM ET
      $BG
      $DICE
      $KDNY
      $QUOT
      Packaged Foods
      Consumer Staples
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $DICE
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    See more
    • SEC Form SC 13D/A filed by DICE Therapeutics Inc. (Amendment)

      SC 13D/A - DICE Therapeutics, Inc. (0001645569) (Subject)

      8/9/23 5:00:12 PM ET
      $DICE
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form SC 13G/A filed by DICE Therapeutics Inc. (Amendment)

      SC 13G/A - DICE Therapeutics, Inc. (0001645569) (Subject)

      7/10/23 10:20:11 AM ET
      $DICE
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form SC 13D/A filed by DICE Therapeutics Inc. (Amendment)

      SC 13D/A - DICE Therapeutics, Inc. (0001645569) (Subject)

      6/23/23 5:10:56 PM ET
      $DICE
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $DICE
    SEC Filings

    See more
    • SEC Form 15-12G filed by DICE Therapeutics Inc.

      15-12G - DICE Therapeutics, Inc. (0001645569) (Filer)

      8/21/23 8:00:26 AM ET
      $DICE
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form EFFECT filed by DICE Therapeutics Inc.

      EFFECT - DICE Therapeutics, Inc. (0001645569) (Filer)

      8/11/23 12:15:08 AM ET
      $DICE
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form S-8 POS filed by DICE Therapeutics Inc.

      S-8 POS - DICE Therapeutics, Inc. (0001645569) (Filer)

      8/9/23 9:47:55 AM ET
      $DICE
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $DICE
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    See more
    • SEC Form 4 filed by Ra Capital Management, L.P.

      4 - DICE Therapeutics, Inc. (0001645569) (Issuer)

      8/9/23 5:00:37 PM ET
      $DICE
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form 4: Tetlow Sharon returned 49,841 shares to the company, closing all direct ownership in the company

      4 - DICE Therapeutics, Inc. (0001645569) (Issuer)

      8/9/23 4:38:19 PM ET
      $DICE
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form 4 filed by Simson Jake

      4 - DICE Therapeutics, Inc. (0001645569) (Issuer)

      8/9/23 4:36:43 PM ET
      $DICE
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $DICE
    Leadership Updates

    Live Leadership Updates

    See more
    • ShouTi Appoints Sharon Tetlow to Board of Directors

      ShouTi Inc., a clinical-stage global biopharmaceutical company developing novel oral therapeutics to treat a wide range of chronic diseases, today announced the appointment of Sharon Tetlow to the company's board of directors. Ms. Tetlow will also serve as chair of the audit committee. "On behalf of the board and management team at ShouTi, I am pleased to welcome Sharon to the board," said Daniel Welch, Chairman of the Board, ShouTi. "Sharon is an accomplished life sciences finance executive whose deep financial strategy and compliance expertise will be instrumental in leading our audit committee. With an outstanding track record of advising biopharmaceutical companies, Sharon's perspectiv

      3/29/22 8:00:00 AM ET
      $CBIO
      $DICE
      $VALN
      Biotechnology: Pharmaceutical Preparations
      Health Care
      Biotechnology: Biological Products (No Diagnostic Substances)
    • DICE Therapeutics Expands Management Team and Board of Directors

      Mary Riley, J.D., appointed as general counselLisa Bowers, MHSA, and Mittie Doyle, M.D., FACR, join board of directors SOUTH SAN FRANCISCO, Calif., March 28, 2022 (GLOBE NEWSWIRE) -- DICE Therapeutics, Inc. (NASDAQ:DICE), a biopharmaceutical company leveraging its proprietary technology platform to build a pipeline of novel oral therapeutic candidates to treat chronic diseases in immunology and other therapeutic areas, today announced the appointment of Mary Riley as general counsel and the additions of Lisa Bowers and Mittie Doyle, M.D., FACR, to DICE's board of directors. Concurrently, Stephen Zachary, Ph.D., will be stepping down from the Company's board. "Mary, Lisa and Mittie are e

      3/28/22 4:05:00 PM ET
      $DICE
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $DICE
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    See more
    • Wells Fargo initiated coverage on DICE Therapeutics with a new price target

      Wells Fargo initiated coverage of DICE Therapeutics with a rating of Equal Weight and set a new price target of $38.00

      5/24/23 7:49:57 AM ET
      $DICE
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Canaccord Genuity initiated coverage on DICE Therapeutics with a new price target

      Canaccord Genuity initiated coverage of DICE Therapeutics with a rating of Buy and set a new price target of $71.00

      5/22/23 7:17:25 AM ET
      $DICE
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Needham initiated coverage on DICE Therapeutics with a new price target

      Needham initiated coverage of DICE Therapeutics with a rating of Buy and set a new price target of $56.00

      3/31/23 7:20:41 AM ET
      $DICE
      Biotechnology: Pharmaceutical Preparations
      Health Care